Extended Characterization of Biologics by High-Resolution Mass Spectrometry
Crystal Bio Solutions, part of Crystal Group, uses Orbitrap high-resolution mass spectrometry (HRMS) with orthogonal chromatographic and electrophoretic methods to define the structure and variants of complex biologics. Work is performed in our biologics CMC analytical laboratory in Natick, Massachusetts for antibodies, multispecifics, ADCs, fusion proteins and other proteins, to support CQA definition, biosimilar analytical similarity, comparability and CMC gap analysis.
HRMS for Biosimilar Programs
Draft FDA guidance issued in October 2025 proposes that a comparative efficacy study may not be necessary for many therapeutic protein biosimilars when a comparative analytical assessment, a PK similarity study and an immunogenicity assessment address residual uncertainty. If finalized as proposed, the analytical package would carry more weight than before. - Structure: intact and subunit mass, peptide mapping targeting complete coverage, disulfides and free thiols
- Microheterogeneity: glycan profiles, PTM levels and charge variants across reference and proposed lots
- Higher-order structure: orthogonal biophysical methods, with HDX-MS through strategic partners
- Function: binding kinetics by SPR through strategic partners
The clinical elements, PK similarity and immunogenicity, can be supported by our Pleasanton bioanalysis laboratory and clinical pharmacology team.
Related reading: The 6 most common analytical gaps in biosimilar programs; HRMS in biologics characterization; Antibody glycosylation
Related Services
Frequently Asked Questions
What is extended characterization of a biologic?
Extended characterization goes beyond routine release methods to define a molecule's structure in detail: its sequence, post-translational modifications, disulfide structure, glycosylation, charge and size variants and higher-order structure. It supports CQA definition, comparability and responses to regulatory questions.
Why use high-resolution mass spectrometry?
HRMS measures mass precisely enough to identify small modifications, such as a 1 Da deamidation, and to locate them at specific residues. It confirms identity and explains what other methods, such as charge variant or size variant profiles, are showing.
Why use more than one enzyme for peptide mapping?
A single enzyme can leave parts of the sequence as peptides that are too short, too long or poorly detected. Combining enzymes increases coverage, usually to the complete sequence, which is needed to confirm the sequence and detect sequence variants with confidence. Any region that remains difficult is confirmed with an orthogonal approach.
What is disulfide scrambling and why does it matter?
Disulfide scrambling means cysteines are linked in a non-native pattern. It can change structure, activity and stability, so disulfide mapping and free thiol measurement are part of characterizing antibodies and other cysteine-rich proteins.
What are HDX-MS and MAPPs used for?
HDX-MS measures hydrogen-deuterium exchange to map epitopes and compare higher-order structure. MAPPs (MHC-associated peptide proteomics) identifies drug-derived peptides presented on MHC class II molecules, which helps locate potential T-cell epitopes for immunogenicity risk assessment. CBS provides HDX-MS and MAPPs through strategic partners and integrates the results with in-house HRMS data.
Can analytical data replace a comparative efficacy study for a biosimilar?
In October 2025 FDA issued draft guidance proposing that a comparative efficacy study may not be necessary for many therapeutic protein biosimilars when comparative analytical data, a human PK similarity study and an immunogenicity assessment address residual uncertainty. The guidance is still a draft (FDA withdrew its 2015 final biosimilarity guidance in March 2026). FDA can still request a clinical study, so the strength of the analytical package, including HRMS characterization of multiple reference and proposed lots, matters for each program.
Which molecule types does CBS characterize?
Monoclonal antibodies, antibody fragments, bispecific and trispecific antibodies, fusion proteins, PEGylated proteins, ADCs, and other proteins and peptides such as cytokines, growth factors and enzymes.
Where is this work performed?
Extended characterization is performed in the CBS biologics CMC analytical laboratory in Natick, Massachusetts.